Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus
Christina G. Katsiari, … , Yuang-Taung Juang, George C. Tsokos
Christina G. Katsiari, … , Yuang-Taung Juang, George C. Tsokos
Published November 1, 2005
Citation Information: J Clin Invest. 2005;115(11):3193-3204. https://doi.org/10.1172/JCI24895.
View: Text | PDF
Research Article Immunology

Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus

  • Text
  • PDF
Abstract

Decreased IL-2 production in systemic lupus erythematosus (SLE) represents a central component of the disease immunopathology. We report that the message, protein, and enzymatic activity of the catalytic subunit of protein phosphatase 2A (PP2Ac), but not PP1, are increased in patients with SLE regardless of disease activity and treatment and in a disease-specific manner. Treatment of SLE T cells with PP2Ac-siRNA decreased the protein levels and activity of PP2Ac in a specific manner and increased the levels of phosphorylated cAMP response element–binding protein and its binding to the IL2 and c-fos promoters, as well as increased activator protein 1 activity, causing normalization of IL-2 production. Our data document increased activity of PP2A as a novel SLE disease-specific abnormality and define a distinct mechanism whereby it represses IL-2 production. We propose the use of PP2Ac-siRNA as a novel tool to correct T cell IL-2 production in SLE patients.

Authors

Christina G. Katsiari, Vasileios C. Kyttaris, Yuang-Taung Juang, George C. Tsokos

×

Figure 8

Options: View larger image (or click on image) Download as PowerPoint
Downregulation of PP2Ac restores IL-2 production and IL2 promoter activi...
Downregulation of PP2Ac restores IL-2 production and IL2 promoter activity in SLE T cells. (A) T cells were transfected with either PP2Ac- or control siRNA. Cells were then stimulated with PMA/A23187 for 3 hours. IL-2 was measured as described in Methods. *P = 0.03 and 0.05 when compared with nontransfected normal T cells and with transfected lupus T cells, respectively; **P = 0.05 compared with nontransfected normal T cells. (B) PP2Ac-siRNA treatment downregulates PP2Ac but not PP2Aa expression. Results from 2 independent experiments with normal T cells are shown (PP2Ac/PP2Aa ratios are noted below the panels). (C) T cells were treated as indicated, and IL-2 was measured. Results from 1 of 2 similar experiments are shown. (D) T cells were transfected with plasmids encoding either the wild-type PP2Ac or DN PP2Ac mutants (H118N or L199P). Twenty hours following transfection, cells were stimulated with PMA/A23187 for 6 hours. P values represent the result of paired t test analysis. (E) Results from the same experiment as shown in D, except that T cells were stimulated with OKT3/anti-CD3 mAbs for 18 hours. (F) T cells were cotransfected with (a) a plasmid encoding an IL2 promoter luciferase construct or an empty vector, (b) a β-galactosidase plasmid, and (c) either PP2Ac- or control siRNA. Following 24 hours of culture, cells were stimulated for 1 hour with PMA/A23187. IL2 promoter activity was assessed as the luciferase activity. Numbers show the fold increase in IL2 promoter activity when compared with stimulated cells in the absence of PP2Ac-siRNA. Results from 1 of 2 similar experiments are presented.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts